The US Food and Drug Administration review of the safety and effectiveness of nonstandardized allergen extracts

Journal of Allergy and Clinical Immunology

Volumn 129, Issue 4, 2012, Pages 1014-1019

  Slater, Jay E ^a   Menzies, Sandra L ^a   Bridgewater, Jennifer ^a   Mosquera, Alexis ^a   Zinderman, Craig E ^a   Ou, Alan C ^a   Maloney, Diane ^a   Cook, Catherine M ^a   Rabin, Ronald L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Allergen extracts; effectiveness; immunotherapy; safety; skin testing

Indexed keywords

ALLERGEN; HOUSE DUST ALLERGEN;

ANGIONEUROTIC EDEMA; BRACKEN FERN; BRONCHOSPASM; CHENOPODIUM; DANDER; DEER; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG LABELING; DRUG NOMENCLATURE; DRUG SAFETY; EPHEDRA; FOOD AND DRUG ADMINISTRATION; HAIR; HAPLORHINI; HUMAN; IMMUNOTHERAPY; LABURNUM; LICENSING; POLLEN; PRIORITY JOURNAL; REVIEW; RHUBARB; RICINUS COMMUNIS; STANDARDIZATION; TRIATOMA;

EID: 84859156905     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.01.066     Document Type: Article

References (24)

1. S.G. Cohen, and R. Evans Allergen immunotherapy in historical perspective Clin Allergy Immunol 21 2008 1 29
2. S.J. Till, and S.R. Durham Immunologic responses to subcutaneous allergen immunotherapy Clin Allergy Immunol 21 2008 59 70
3. Drug amendments of 1962. Pub L No. 87-781, 76 Stat 780.
4. Certain biological products; request for data and information regarding safety, effectiveness, and labeling review, 39 Federal Register 21176-21177 (June 19, 1974).
5. Biological products; allergenic extracts; implementation of efficacy review, 50 Federal Register 3082-3288 (January 23, 1985).
6. Licensing; reclassification procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use, 47 Federal Register 44062-44073 (October 5, 1982).
7. Reclassification procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use (2011) (21 CFR §601.26).
8. Panel on review of allergenic extracts Category IIIA reclassification, final report, December 1983. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/Allergenics/UCM271333.pdf. Accessed December 27, 2011.
9. Biological products; allergenic extracts classified in Category IIIB; final order; revocation of licenses, 59 Federal Register 59228-59237 (November 16, 1994).
10. K.S. Morrow, and J.E. Slater Regulatory aspects of allergen vaccines in the US Clin Rev Allergy Immunol 21 2001 141 152
11. Allergenic Products Advisory Committee, April 7, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/cber05.html#AllergenicProducts. Accessed December 27, 2011.
12. Allergenic Products Advisory Committee, September 13, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/cber06.html#AllergenicProducts. Accessed December 27, 2011.
13. Allergenics Advisory Review Panel Reports. Available at: http://www.fda.gov/BiologicsBloodVaccines/Allergenics/ucm272115.htm. Accessed December 27, 2011.
14. Allergenic Products Advisory Committee meeting: table of non-standardized allergen extracts. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ AllergenicProductsAdvisoryCommittee/UCM274718.pdf. Accessed December 27, 2011.
15. D.I. Bernstein, and T. Epstein Systemic reactions to subcutaneous allergen immunotherapy Immunol Allergy Clin North Am 31 2011 241 249
16. Allergen immunotherapy: a practice parameter, second update J Allergy Clin Immunol 120 suppl 2007 S25 S85
17. MedWatch Online Voluntary Reporting Form (3500). Available at: https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm. Accessed December 27, 2011.
18. House dust extracts should be placed in Category II. FDC Reports (The Pink Sheet) 1986;48:17.
19. Integrated Taxonomic Information System. Available at: www.itis.gov. Accessed December 27, 2011.
20. DNA-based seafood identification. Available at: http://www.fda.gov/Food/ FoodSafety/Product-SpecificInformation/Seafood/DNAspeciation/default.htm. Accessed December 27, 2011.
21. ATCC. Available at www.atcc.org. Accessed December 27, 2011.
22. Center for Biologics Evaluation and Research report of scientific and medical literature and information on non-standardized allergenic extracts in the diagnosis and treatment of allergic disease; availability. 76 Federal Register 59407-59408 (September 26, 2011).
23. Allergenic Products Advisory Committee, October 25, 2011. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ BloodVaccinesandOtherBiologics/AllergenicProductsAdvisoryCommittee/ucm247212. htm. Accessed December 27, 2011.
24. Center for Biologics Evaluation and Research report of scientific and medical literature and information on non-standardized allergenic extracts in the diagnosis and treatment of allergic disease; extension of comment period, 76 Federal Register 71045-71046 (November 16, 2011).